Abstract:Four series of hypoxia-inducible factor-1 alpha (HIF-1α) functioning derivatives stemming from modifications to the C-29 carboxyl group of celastrol were designed and synthesized, and their anticancer activities were evaluated. To address the structure and activity relationship of each derivative, extensive structural changes were made. HRE luciferase reporter assay demonstrated that 12 modified compounds showed superior HIF-1α inhibitory activity. Among them, compound C6 exhibited the best features: firstly, the strongest HIF-1α inhibitory activity (IC50 = 0.05 μM, 5-fold higher than that of celastrol); secondly, lower cytotoxicity (22-fold lower, C6-16.85 μM vs celastrol-0.76 μM). Thus, the safety factor of C6 was about 112 times higher than that of celastrol. Western blot assay indicated that C6 may inhibit the expression of HIF-1α protein in cells. Additionally, C6 hindered tumor cell cloning, migration and induced cell apoptosis. It is worth mentioning that in the mouse tumor xenograft model, C6 (10 mg/kg) displayed good antitumor activity in vivo, showing a better inhibition rate (74.03%) than the reference compound 5-fluorouracil (inhibition rate, 59.58%). However, the celastrol treatment group experienced collective death after four doses of the drug. Moreover, C6 minimally affected the mouse weight, indicating that its application in vivo has little toxic effect. H&E staining experiments show that it could also exacerbate the degree of tumor cell damage. The results of water solubility experiment show that the solubility of C6 is increased by 1.36 times than that of celastrol. In conclusion, C6 is a promising antitumor agent through HIF-1α pathway.

Design, synthesis, and evaluation of antitumor activity of novel C‐6 sulfhydryl‐substituted and 20‐substituted derivatives of celastrol

Design, Synthesis and Antitumor Evaluation of Novel Celastrol Derivatives

Design, Synthesis and Biological Evaluation of C(6)-Modified Celastrol Derivatives As Potential Antitumor Agents

Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway

Synthesis and Biological Evaluation of Celastrol Derivatives with Improved Cytotoxic Selectivity and Antitumor Activities

Synthesis of 3- and 29-Substituted Celastrol Derivatives and Structure-Activity Relationship Studies of Their Cytotoxic Activities.

Synthesis and Characterisation of Celastrol Derivatives As Potential Anticancer Agents

Celastrol Inhibits Cancer Metastasis by Suppressing M2-like Polarization of Macrophages.

Antitumor effect of novel celastrol analogues in vitro

Design And Synthesis Of Novel Celastrol Derivative And Its Antitumor Activity In Hepatoma Cells And Antiangiogenic Activity In Zebrafish

Synthesis and Biological Evaluation of a Series of Novel Celastrol Derivatives with Amino Acid Chain

Design, Synthesis and Biological Evaluation of C(6)-Indole Celastrol Derivatives As Potential Antitumor Agents

Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy

Design and Synthesis of Novel Celastrol Derivatives as Potential Anticancer Agents against Gastric Cancer Cells

Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents

Discovery of Novel Celastrol–Imidazole Derivatives with Anticancer Activity In Vitro and In Vivo

Antitumor Agents 288: Design, Synthesis, SAR, and Biological Studies of Novel Heteroatom-Incorporated Antofine and Cryptopleurine Analogues As Potent and Selective Antitumor Agents.

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Synthesis and Biological Evaluation of Celastrol Derivatives As Potent Antitumor Agents with STAT3 Inhibition.

Quantitative chemical proteomics reveals anti-cancer targets of Celastrol in HCT116 human colon cancer cells

Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.